Cluster Headache Drugs: Medications That Cause or Treat It

What Cluster Headache Actually Is

Cluster headache is a primary headache disorder classified under the trigeminal autonomic cephalalgias (TACs) in the ICHD-3 criteria published by the International Headache Society. Attacks produce severe, unilateral periorbital pain accompanied by ipsilateral autonomic features: ptosis, miosis, lacrimation, conjunctival injection, nasal congestion, or rhinorrhea. The pain peaks within minutes and lasts 15 to 180 minutes untreated.

The term "cluster" refers to the temporal pattern. Bouts typically last 6 to 12 weeks, recur at the same calendar season, and feature one to eight attacks per day, often at predictable nocturnal hours. A population-based study in Norway (N=51,383) estimated lifetime prevalence at 0.1%, with men affected roughly three times more often than women [1]. Hypothalamic activation on the ipsilateral side has been demonstrated by PET imaging, and this finding now anchors the pathophysiological model linking circadian rhythmicity to trigeminovascular activation [2].

Diagnosis is clinical. No imaging or lab test confirms cluster headache, though MRI is recommended once to rule out secondary causes such as pituitary adenoma or cavernous sinus pathology. The diagnostic delay averages 5.3 years according to a European survey of 1,163 patients published in Cephalalgia [3].

Acute Treatment: Stopping an Attack in Progress

The two treatments with the strongest evidence for aborting a cluster attack are high-flow oxygen and subcutaneous sumatriptan. Both work fast. Both are well-supported by randomized controlled data.

High-flow oxygen at 12-15 L/min delivered through a non-rebreather mask for 15-20 minutes achieved pain freedom or adequate relief in 78% of attacks versus 20% for room air in a crossover RCT (N=76) published in JAMA [4]. Oxygen has no systemic side effects. It can be repeated without dose limits. The practical barrier is access: patients need a home concentrator or cylinder with a high-flow regulator, and insurance coverage varies by state.

Sumatriptan 6 mg subcutaneous injection produced pain freedom at 15 minutes in 75% of treated attacks versus 32% for placebo in the key trial [5]. The auto-injector format matters because oral triptans are too slow for a 15-to-180-minute attack window. Sumatriptan nasal spray 20 mg is an alternative when injection is refused, though onset is slower (response at 30 minutes). Zolmitriptan nasal spray 5 mg also has supporting evidence from a double-blind trial (N=92) showing a 50% response at 30 minutes versus 30.2% placebo [6].

What not to use acutely. Oral analgesics, NSAIDs, and opioids have no role. They are too slow, and opioids risk medication-overuse headache. Ergotamine suppositories have historical use but carry vasoconstrictor risks and are rarely first-line today.

Preventive Medications: Reducing Bout Frequency

Preventive therapy is the backbone of cluster headache management because acute treatments alone do not reduce the burden of daily recurrent attacks over a 6-to-12-week bout. The goal is to suppress attacks until the bout remits naturally.

Verapamil

Verapamil is the most widely prescribed cluster headache preventive worldwide, recommended as first-line by the American Headache Society and the European guideline consortium. Doses range from 240 mg/day to 960 mg/day, titrated in 80 mg increments every 10-14 days. A double-blind crossover trial (N=30) showed verapamil 360 mg/day reduced attack frequency by approximately 50% compared with placebo [7].

ECG monitoring is mandatory. High-dose verapamil can prolong the PR interval and cause bradycardia. Baseline ECG should be obtained before starting, and repeat ECGs are recommended with each dose increase above 480 mg/day. The AHS guideline notes that first-degree heart block occurs in up to 20% of patients at doses above 720 mg [7].

Galcanezumab (Emgality)

Galcanezumab became the first and, as of 2026, only FDA-approved preventive for episodic cluster headache. The phase 3 trial (N=106) demonstrated a reduction of 8.7 attacks over weeks 1-3 versus 5.2 for placebo (P=0.04) with a single 300 mg subcutaneous loading dose [8]. The FDA approval was based on this data, though the drug did not meet its primary endpoint in a separate chronic cluster headache trial [9].

The dosing for cluster headache (300 mg as three consecutive 100 mg injections at bout onset) differs from the migraine indication (240 mg loading, then 120 mg monthly). Clinicians should specify the cluster headache regimen on prescriptions to avoid pharmacy confusion.

Lithium

Lithium carbonate 600-1 to 200 mg/day has been used for chronic cluster headache since the 1970s. An open-label series (N=28) reported a response rate of 78% [10]. However, no large placebo-controlled RCT exists. Lithium requires serum level monitoring (target 0.6-1.0 mEq/L), thyroid function checks, and renal function surveillance. Side effects include tremor, polyuria, and hypothyroidism.

Topiramate

Topiramate 100-200 mg/day is considered a second-line or third-line agent. Open-label data suggest benefit, but RCT-level evidence is limited [11]. Cognitive dulling and weight loss are common side effects. It may be an option for patients who cannot tolerate verapamil or lithium.

Melatonin

Melatonin 10 mg nightly showed a significant reduction in cluster attack frequency in a small double-blind RCT (N=20) [12]. Its favorable safety profile makes it a reasonable adjunct, particularly given the hypothalamic circadian dysregulation underlying cluster headache pathophysiology.

Transitional (Bridge) Therapies

Preventive drugs like verapamil take 2-3 weeks to reach therapeutic doses. During this gap, transitional therapies suppress attacks.

Corticosteroids are the most common bridge. A typical regimen is prednisone 60-80 mg/day for 5 days followed by a taper over 2-3 weeks. A retrospective study of 97 patients found that 77% responded to a short steroid course, though attacks often returned during taper [13]. The AHS recommends limiting steroid bridges to once or twice per year to avoid adrenal suppression and bone loss.

Greater occipital nerve (GON) block using a local anesthetic (bupivacaine 2.5-5 mL) with or without corticosteroid (methylprednisolone or betamethasone) injected at the ipsilateral occipital nerve is an effective bridge. A randomized trial (N=43) showed that suboccipital steroid injection reduced attack frequency by more than 50% in 85% of participants for at least four weeks [14].

Dihydroergotamine (DHE) can be given as an inpatient IV protocol over 3-5 days for refractory bouts. DHE is contraindicated within 24 hours of triptan use and in patients with coronary artery disease or uncontrolled hypertension.

Drugs That Can Trigger Cluster Headache Attacks

Certain medications act as pharmacological triggers during an active cluster bout. Outside a bout, these same agents typically do not provoke attacks, which is a distinctive feature of the disorder.

Nitroglycerin and Nitric Oxide Donors

Nitroglycerin (sublingual or transdermal) is the best-documented pharmacological trigger. A provocation study demonstrated that sublingual nitroglycerin 1 mg induced a cluster-like attack in 72% of patients during an active bout versus 0% during remission [15]. This observation helped establish the nitric oxide pathway as central to cluster headache pathophysiology.

Patients on chronic nitroglycerin or isosorbide mononitrate for angina who develop cluster bouts may need cardiology co-management to identify alternative antianginals. Calcium channel blockers (including verapamil, which also serves as a cluster preventive) may address both conditions.

Alcohol

Alcohol is the most commonly reported trigger, cited by 50-80% of cluster headache patients during active bouts [3]. Even small amounts (half a glass of wine) can provoke an attack within 30-60 minutes. The mechanism likely involves alcohol-mediated vasodilation and histamine release. Patients in an active bout should avoid all alcohol.

Phosphodiesterase-5 Inhibitors

Sildenafil, tadalafil, and vardenafil have been reported to trigger cluster attacks in case series [16]. These drugs work through nitric oxide/cGMP pathway potentiation, overlapping with the nitroglycerin mechanism. Patients with cluster headache who require PDE5 inhibitors for erectile dysfunction should discuss timing relative to their cluster periods with their prescribing physician.

Histamine

Histamine infusion was the original laboratory provocateur in Horton's early cluster headache research. Though not a prescribed drug, histamine-releasing compounds (certain contrast agents, vancomycin rapid infusion causing "red man syndrome") could theoretically provoke attacks during an active bout.

Emerging and Investigational Therapies

Several newer approaches are under investigation or gaining off-label traction.

Fremanezumab, another anti-CGRP monoclonal antibody, did not meet its primary endpoint in a phase 3 chronic cluster headache trial (N=571), consistent with galcanezumab's failure in the chronic subtype [17]. The repeated failure of CGRP-targeted drugs in chronic cluster headache suggests pathophysiological differences between episodic and chronic forms.

Non-invasive vagus nerve stimulation (nVNS) using the gammaCore device received FDA clearance for acute cluster headache treatment. The ACT2 study (N=48 episodic, N=44 chronic) found that 48% of episodic cluster patients achieved pain freedom at 15 minutes with nVNS versus 6% sham (P<0.01), though chronic patients showed no significant benefit [18].

Sphenopalatine ganglion stimulation via an implanted microstimulator (Pulsante device) demonstrated that on-demand stimulation achieved pain relief in 67.1% of treated attacks in the Pathway CH-1 study (N=28) [19]. The procedure is invasive, requiring device implantation in the pterygopalatine fossa, and is currently available only at specialized centers.

Psilocybin and related tryptamines are generating significant patient-driven and research interest. A survey of 496 cluster headache patients published in Neurology found that 52% of psilocybin users reported abortion of an acute attack, and 64% reported that a full dose interrupted a cluster period [20]. Randomized controlled data are still needed. A phase 2 trial at Yale is evaluating psilocybin for treatment-resistant cluster headache.

When to Escalate Care

Not every cluster headache responds to standard therapy. Roughly 10-20% of patients are refractory. The European Headache Federation defines refractory chronic cluster headache as failure of adequate trials of at least three preventive drugs (including verapamil at ≥960 mg/day and lithium at therapeutic serum levels) [21].

Refractory patients should be referred to a headache specialist center for consideration of:

• Occipital nerve stimulation (ONS), which showed a 66.7% responder rate in a long-term follow-up study (median 6.1 years, N=30) [22]
• Deep brain stimulation of the posterior hypothalamus (reserved for the most intractable cases)
• Repeated GON blocks or sphenopalatine ganglion blockade as temporizing measures
• Clinical trial enrollment

A diagnostic re-evaluation is also warranted to confirm that the headache meets ICHD-3 criteria, as secondary causes and other TACs (paroxysmal hemicrania, SUNCT/SUNA) require different treatment. Indomethacin-responsive headaches, for instance, point away from cluster headache toward paroxysmal hemicrania.

Building a Treatment Protocol

For a patient presenting in an active episodic cluster bout, a practical sequencing approach includes:

1. Acute rescue: prescribe both high-flow oxygen (12-15 L/min via non-rebreather, 15-20 min) and sumatriptan 6 mg subcutaneous auto-injector (max 2 injections/24 hours, separated by at least 1 hour)
2. Bridge therapy: start prednisone 60 mg/day for 5 days with a 2-week taper, or perform an ipsilateral GON block
3. Preventive titration: begin verapamil 80 mg TID, obtain baseline ECG, increase by 80 mg every 10-14 days to 480-720 mg/day as tolerated
4. If verapamil fails or is contraindicated: consider galcanezumab 300 mg SC (episodic only), lithium 300 mg BID titrated to serum levels, or topiramate 50-200 mg/day
5. Lifestyle measures: absolute alcohol avoidance during the bout, consistent sleep-wake schedule, avoidance of known vasodilator medications

The 2016 AHS evidence assessment found that subcutaneous sumatriptan and high-flow oxygen carry Level A (established efficacy) recommendations for acute treatment, while verapamil holds Level C due to limited RCT data despite decades of clinical use and universal guideline endorsement [23].